Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
The Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin
Sacramento Pediatric Gastroenterology
200 participants
Jul 1, 2010
INTERVENTIONAL
Conditions
Summary
The purpose of this study is twofold. First, is to determine whether vancomycin is effective in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and if so, by what mechanism. Secondly, to characterize human intestinal microbial communities and their interactions with the host.
Eligibility
Inclusion Criteria2
- Persons who have primary sclerosing cholangitis, biliary atresia, a chronic intestinal disorder or who are undergoing upper or lower endoscopy.
- Persons who have primary sclerosing cholangitis or biliary atresia who are good candidates for vancomycin therapy.
Exclusion Criteria2
- Patients that have taken antibiotics and/or immunomodulators within the last 3 months will be excluded as this will alter the original bacterial flora.
- Females who are pregnant may not participate.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oral Vancomycin is given to PSC or BA participants
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02137668